Home › Compare › WOSSF vs ABBV
WOSSF yields 5.58% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, WOSSF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WOSSF + ABBV for your $10,000?
Water Oasis Group Limited, an investment holding company, provides beauty and related wellness services. The company operates through Product and Service segments. It provides general, specialist, and medical beauty services to high-end, mid-range, and mass-market consumer sectors for men and women. It also operates an online florist shop under the Oasis Florist brand; and a manicure business under the Oasis Nail brand. In addition, the company offers skincare products under the Glycel and Eurobeauté brands, and medical beauty products line under the DermaSynergy brand; and retails and distributes skincare products of Erno Laszlo and H2O+ brands. Further, it is involved in the online sale of skincare products; provision of beauty equipment; and property holding business, as well as produces and sells cold pressed fruit juice. As of September 30, 2021, the company operated a total of 17 Oasis Beauty centers in Hong Kong comprising 15 Oasis Beauty and 2 Oasis Homme centers; and 3 self-managed Oasis Beauty centers in Beijing, the People's Republic of China. Water Oasis Group Limited was founded in 1998 and is headquartered in Causeway Bay, Hong Kong.
Full WOSSF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.